Base de dados : MEDLINE
Pesquisa : C08.381.483 [Categoria DeCS]
Referências encontradas : 7278 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 728 ir para página                         

  1 / 7278 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464801
[Au] Autor:Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
[Ad] Endereço:Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 3-1-3, Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
[Ti] Título:Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
[So] Source:BMC Cancer;17(1):302, 2017 May 02.
[Is] ISSN:1471-2407
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lung cancer. Our aim was to analyze the association between serum biomarkers sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), and clinical characteristics in patients diagnosed with ILD-AA. METHODS: Between April 2011 and March 2016, 1224 advanced lung cancer patients received cytotoxic agents and epidermal growth factor receptor tyrosine kinase inhibitors at Juntendo University Hospital and Juntendo University Urayasu Hospital. Of these patients, those diagnosed with ILD-AA were enrolled in this case control study. ΔKL-6 and ΔSP-D were defined as the difference between the levels at the onset of ILD-AA and their respective levels prior to development of ILD-AA. We evaluated KL-6 and SP-D at the onset of ILD-AA, ΔKL-6 and ΔSP-D, the risk factors for death related to ILD-AA, the chest high resolution computed tomography (HRCT) findings, and survival time in patients diagnosed with ILD-AA. RESULTS: Thirty-six patients diagnosed with ILD-AA were enrolled in this study. Among them, 14 patients died of ILD-AA. ΔSP-D in the patients who died was significantly higher than that in the patients who survived. However, ΔKL-6 did not differ significantly between the two groups. Moreover, ΔSP-D in patients who exhibited diffuse alveolar damage was significantly higher than that in the other patterns on HRCT. Receiver operating characteristic curve analysis was used to set the optimal cut off value for ΔSP-D at 398 ng/mL. Survival time for patients with high ΔSP-D (≥ 398 ng/mL) was significantly shorter than that for patients with low ΔSP-D. Multivariate analysis revealed that ΔSP-D was a significant prognostic factor of ILD-AA. CONCLUSIONS: This is the first research to evaluate high ΔSP-D (≥ 398 ng/mL) in patients with ILD-AA and to determine the risk factors for ILD-AA in advanced lung cancer patients. ΔSP-D might be a serum prognostic biomarker of ILD-AA. Clinicians should evaluate serum SP-D during chemotherapy and should carefully monitor the clinical course in patients with high ΔSP-D.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Biomarcadores/sangue
Doenças Pulmonares Intersticiais
Neoplasias Pulmonares
Proteína D Associada a Surfactante Pulmonar/sangue
[Mh] Termos MeSH secundário: Idoso
Antineoplásicos/uso terapêutico
Estudos de Casos e Controles
Feminino
Seres Humanos
Pulmão
Doenças Pulmonares Intersticiais/induzido quimicamente
Doenças Pulmonares Intersticiais/complicações
Doenças Pulmonares Intersticiais/diagnóstico
Doenças Pulmonares Intersticiais/mortalidade
Neoplasias Pulmonares/complicações
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/mortalidade
Masculino
Prognóstico
Curva ROC
Análise de Sobrevida
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers); 0 (Pulmonary Surfactant-Associated Protein D)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12885-017-3285-6


  2 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289262
[Au] Autor:Chen F; Li S; Wang T; Shi J; Wang G
[Ad] Endereço:Department of Rheumatology, China-Japan Friendship Hospital, Yinghua East Road, Chaoyang District, Beijing, China.
[Ti] Título:Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
[So] Source:Am J Med Sci;355(1):48-53, 2018 01.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The aim of this study was to compare the heterogeneity of interstitial lung disease (ILD) in patients with polymyositis and dermatomyositis (PM/DM) according to serological type. METHODS: A total of 182 patients with PM/DM-ILD were observed retrospectively. Antiaminoacyl-tRNA synthetase (ARS) and antimelanoma differentiation-associated gene5 (MDA5) antibodies were screened using immunoblotting approach. The patients with ILD were divided into 3 groups: MDA5 (with anti-MDA5 antibody), ARS (with anti-ARS antibody) and MSN (without anti-MDA5 or anti-ARS antibody) group. Pulmonary features, treatment responses and prognoses were compared among the groups. RESULTS: A higher percentage of rapidly progressive ILD (RP-ILD) occurrences (55.8% versus 25% versus 16.9%, P < 0.001) was observed in the MDA5 group compared to ARS and MSN groups. The MSN group experienced lower dyspnea (48.2% versus 79% versus 71.4%, P = 0.001) and fever (18.1% versus 39.5% versus 37.5%, P = 0.01) frequencies compared to MDA5 and ARS groups. Response to 6-month treatment among 95 patients showed highest deterioration ratio (70%, P = 0.001) of ILD in the MDA5 group. Additionally, the highest frequency of ILD improvement (60%, P = 0.04) was observed in the ARS group. During the observation period, 24 patients died of respiratory failure. The 5-year survival rates were significantly lower in MDA5 group (50.2%) compared to ARS group (97.7%) or the MSN group (91.4%) (P < 0.001). CONCLUSIONS: MDA5-ILD was associated with severe pulmonary manifestations, poor response to treatment and aggravated prognosis. The ARS-ILD group had favorable treatment response and prognosis. MSN-ILD patients had relatively worse treatment response and prognosis compared to the ARS group, even though they expressed milder pulmonary manifestation.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Dermatomiosite/sangue
Doenças Pulmonares Intersticiais/sangue
Polimiosite/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
China/epidemiologia
Dermatomiosite/diagnóstico
Dermatomiosite/mortalidade
Feminino
Seres Humanos
Doenças Pulmonares Intersticiais/diagnóstico
Doenças Pulmonares Intersticiais/epidemiologia
Masculino
Meia-Idade
Polimiosite/diagnóstico
Polimiosite/mortalidade
Estudos Retrospectivos
Taxa de Sobrevida/tendências
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Autoantibodies)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  3 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386436
[Au] Autor:Komada F
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Himeji Dokkyo University.
[Ti] Título:[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
[So] Source:Yakugaku Zasshi;138(2):229-235, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: The aim of this study was to investigate the time-to-onset of drug-induced interstitial lung disease (DILD) following the administration of small molecule molecularly-targeted drugs via the use of the spontaneous adverse reaction reporting system of the Japanese Adverse Drug Event Report database. DILD datasets for afatinib, alectinib, bortezomib, crizotinib, dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, osimertinib, sorafenib, sunitinib, temsirolimus, and tofacitinib were used to calculate the median onset times of DILD and the Weibull distribution parameters, and to perform the hierarchical cluster analysis. The median onset times of DILD for afatinib, bortezomib, crizotinib, erlotinib, gefitinib, and nilotinib were within one month. The median onset times of DILD for dasatinib, everolimus, lapatinib, osimertinib, and temsirolimus ranged from 1 to 2 months. The median onset times of the DILD for alectinib, imatinib, and tofacitinib ranged from 2 to 3 months. The median onset times of the DILD for sunitinib and sorafenib ranged from 8 to 9 months. Weibull distributions for these drugs when using the cluster analysis showed that there were 4 clusters. Cluster 1 described a subgroup with early to later onset DILD and early failure type profiles or a random failure type profile. Cluster 2 exhibited early failure type profiles or a random failure type profile with early onset DILD. Cluster 3 exhibited a random failure type profile or wear out failure type profiles with later onset DILD. Cluster 4 exhibited an early failure type profile or a random failure type profile with the latest onset DILD.
[Mh] Termos MeSH primário: Sistemas de Notificação de Reações Adversas a Medicamentos
Bortezomib/efeitos adversos
Carbazóis/efeitos adversos
Bases de Dados como Assunto
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Doenças Pulmonares Intersticiais/induzido quimicamente
Piperidinas/efeitos adversos
Quinazolinas/efeitos adversos
[Mh] Termos MeSH secundário: Análise por Conglomerados
Dasatinibe/efeitos adversos
Conjuntos de Dados como Assunto
Seres Humanos
Japão/epidemiologia
Doenças Pulmonares Intersticiais/epidemiologia
Terapia de Alvo Molecular/efeitos adversos
Tamanho da Partícula
Pirazóis/efeitos adversos
Piridinas/efeitos adversos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CH5424802); 0 (Carbazoles); 0 (Piperidines); 0 (Pyrazoles); 0 (Pyridines); 0 (Quinazolines); 41UD74L59M (afatinib); 53AH36668S (crizotinib); 69G8BD63PP (Bortezomib); RBZ1571X5H (Dasatinib)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00194


  4 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470010
[Au] Autor:Li L; Chen S; Wen X; Wang Q; Lv G; Li J; Yang F; Zhang F; Li Y
[Ad] Endereço:Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
[Ti] Título:Positive Association between Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population.
[So] Source:Biomed Res Int;2017:2905987, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Single nucleotide polymorphisms (SNPs) in and genes have been shown to be associated with several autoimmune diseases, although whether these genes are susceptibility genes for dermatomyositis/polymyositis (DM/PM) has, to date, not been reported. This study aimed to investigate the potential associations of these SNPs with DM/PM in a Chinese Han population. Five SNPs in (rs2205960, rs844644, and rs844648) and (rs6859219, rs7731626) genes were genotyped using the SequenomMassArray system in 2297 Chinese individuals. In total, 1017 DM/PM patients and 1280 gender-matched healthy controls were genotyped. No significant associations were observed in DM/PM patients for the five SNPs analyzed. The association between SNPs and interstitial lung disease (ILD) was also investigated. Both DM-ILD ( = 0.030, OR = 0.65, 95% CI: 0.47-0.88) and DM/PM-ILD ( = 0.015, OR = 0.67, 95% CI: 0.51-0.87) exhibited a significant association with the rs7731626-A allele. Rs7731626-A was less frequently found in DM-ILD and DM/PM-ILD patients compared with healthy controls. This is the first study to demonstrate a positive association between polymorphism and DM-ILD and DM/PM-ILD. A decreased frequency of rs7731626-A in DM-ILD and DM/PM-ILD patients suggests that the A variant may be protective against DM/PM-ILD.
[Mh] Termos MeSH primário: Proteínas de Transporte/genética
Dermatomiosite/genética
Predisposição Genética para Doença
Doenças Pulmonares Intersticiais/genética
[Mh] Termos MeSH secundário: Adulto
Alelos
China
Dermatomiosite/complicações
Dermatomiosite/patologia
Feminino
Estudos de Associação Genética
Genótipo
Seres Humanos
Doenças Pulmonares Intersticiais/complicações
Doenças Pulmonares Intersticiais/patologia
Masculino
Meia-Idade
Polimorfismo de Nucleotídeo Único
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ANKRD55 protein, human); 0 (Carrier Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1155/2017/2905987


  5 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29297205
[Au] Autor:Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
[Ad] Endereço:Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Commercial Rd, Melbourne, Australia, 3004.
[Ti] Título:Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
[So] Source:Cochrane Database Syst Rev;1:CD010908, 2018 Jan 03.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Approximately one-third of individuals with interstitial lung disease (ILD) have associated connective tissue disease (CTD). The connective tissue disorders most commonly associated with ILD include scleroderma/systemic sclerosis (SSc), rheumatoid arthritis, polymyositis/dermatomyositis, and Sjögren's syndrome. Although many people with CTD-ILD do not develop progressive lung disease, a significant proportion do progress, leading to reduced physical function, decreased quality of life, and death. ILD is now the major cause of death amongst individuals with systemic sclerosis.Cyclophosphamide is a highly potent immunosuppressant that has demonstrated efficacy in inducing and maintaining remission in autoimmune and inflammatory illnesses. However this comes with potential toxicities, including nausea, haemorrhagic cystitis, bladder cancer, bone marrow suppression, increased risk of opportunistic infections, and haematological and solid organ malignancies.Decision-making in the treatment of individuals with CTD-ILD is difficult; the clinician needs to identify those who will develop progressive disease, and to weigh up the balance between a high level of need for therapy in a severely unwell patient population against the potential for adverse effects from highly toxic therapy, for which only relatively limited data on efficacy can be found. Similarly, it is not clear whether histological subtype, disease duration, or disease extent can be used to predict treatment responsiveness. OBJECTIVES: To assess the efficacy and adverse effects of cyclophosphamide in the treatment of individuals with CTD-ILD. SEARCH METHODS: We performed searches on CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to May 2017. We handsearched review articles, clinical trial registries, and reference lists of retrieved articles. SELECTION CRITERIA: We included randomised controlled parallel-group trials that compared cyclophosphamide in any form, used individually or concomitantly with other immunomodulating therapies, versus non-cyclophosphamide-containing therapies for at least six months, with follow-up of at least 12 months from the start of treatment. DATA COLLECTION AND ANALYSIS: We imported studies identified by the search into a reference manager database. We retrieved the full-text versions of relevant studies, and two review authors independently extracted data. Primary outcomes were change in lung function (change in forced vital capacity (FVC) % predicted and diffusing capacity of the lung for carbon monoxide (DLCO) % predicted), adverse events, and health-related quality of life measures. Secondary outcomes included all-cause mortality, dyspnoea, cough, and functional exercise testing. When appropriate, we performed meta-analyses and subgroup analyses by severity of lung function, connective tissue disease diagnosis, and radiological pattern of fibrosis. We assessed the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and created 'Summary of findings' tables. MAIN RESULTS: We included in the analysis four trials with 495 participants (most with systemic sclerosis). We formed two separate comparisons: cyclophosphamide versus placebo (two trials, 195 participants) and cyclophosphamide versus mycophenolate (two trials, 300 participants). We found evidence to be of low quality, as dropout rates were high in the intervention groups, and as we noted a wide confidence interval around the effect with small differences, which affected the precision of results.The data demonstrates significant improvement in lung function with cyclophosphamide compared with placebo (post-treatment FVC % mean difference (MD) 2.83, 95% confidence interval (CI) 0.80 to 4.87; P = 0.006) but no significant difference in post-treatment DLCO (% MD -1.68, 95% CI -4.37 to 1.02; P = 0.22; two trials, 182 participants).Risk of adverse effects was increased in the cyclophosphamide treatment groups compared with the placebo groups, in particular, haematuria, leukopenia, and nausea, leading to a higher rate of withdrawal from cyclophosphamide treatment. The data demonstrates statistically significant improvement in one-measure of quality of life in one trial favouring cyclophosphamide over placebo and clinically and statistically significant improvement in breathlessness in one trial favouring cyclophosphamide compared with placebo, with no significant impact on mortality.Trialists reported no significant impact on lung function when cyclophosphamide was used compared with mycophenolate at 12 months (FVC % MD -0.82, 95% CI -3.95 to 2.31; P = 0.61; two trials, 149 participants; DLCO % MD -1.41, 95% CI -10.40 to 7.58; P = 0.76; two trials, 149 participants).Risk of side effects was increased with cyclophosphamide versus mycophenolate, in particular, leukopenia and thrombocytopenia.The data demonstrates no significant impact on health-related quality of life, all-cause mortality, dyspnoea, or cough severity in the cyclophosphamide group compared with the mycophenolate group. No trials reported outcomes associated with functional exercise tests.We performed subgroup analysis to determine whether severity of lung function, connective tissue disease diagnosis, or radiological pattern had any impact on outcomes. One trial reported that cyclophosphamide protected against decreased FVC in individuals with worse fibrosis scores, and also showed that cyclophosphamide may be more effective in those with worse lung function. No association could be made between connective tissue disease diagnosis and outcomes. AUTHORS' CONCLUSIONS: This review, which is based on studies of varying methodological quality, demonstrates that overall, in this population, small benefit may be derived from the use of cyclophosphamide in terms of mean difference in % FVC when compared with placebo, but not of the difference in % DLCO, or when compared with mycophenolate. Modest clinical improvement in dyspnoea may be noted with the use of cyclophosphamide. Clinical practice guidelines should advise clinicians to consider individual patient characteristics and to expect only modest benefit at best in preserving FVC. Clinicians should carefully monitor for adverse effects during treatment and in the years thereafter.Further studies are required to examine the use of cyclophosphamide; they should be adequately powered to compare outcomes within different subgroups, specifically, stratified for extent of pulmonary infiltrates on high-resolution computed tomography (HRCT) and skin involvement in SSc. Studies on other forms of connective tissue disease are needed. Researchers may consider comparing cyclophosphamide (a potent immunosuppressant) versus antifibrotic agents, or comparing both versus placebo, in particular, for those with evidence of rapidly progressive fibrotic disease, who may benefit the most.
[Mh] Termos MeSH primário: Doenças do Tecido Conjuntivo/tratamento farmacológico
Ciclofosfamida/uso terapêutico
Imunossupressores/uso terapêutico
Doenças Pulmonares Intersticiais/tratamento farmacológico
[Mh] Termos MeSH secundário: Doenças do Tecido Conjuntivo/complicações
Ciclofosfamida/efeitos adversos
Seres Humanos
Imunossupressores/efeitos adversos
Pulmão/efeitos dos fármacos
Doenças Pulmonares Intersticiais/complicações
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
Escleroderma Sistêmico
Capacidade Vital/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD010908.pub2


  6 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461123
[Au] Autor:Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
[Ad] Endereço:Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
[Ti] Título:The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
[So] Source:Respir Med;127:57-64, 2017 Jun.
[Is] ISSN:1532-3064
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Anti-aminoacyl transfer RNA synthetase antibodies (anti-ARS) are a group of myositis-specific autoantibodies that are detected in the sera of patients with polymyositis and dermatomyositis (PM/DM) and also in those of patients with idiopathic interstitial pneumonias without any connective tissue disease (CTD), including PM/DM. Although we reported the clinical characteristics of interstitial lung disease with anti-ARS antibodies (ARS-ILD) with and without PM/DM, the long-term prognosis of ARS-ILD remains undetermined. As our previous studies revealed that ARS-ILD without PM/DM was similar to CTD-associated ILD, and that ARS-ILD with PM/DM was radiologically suggestive of a nonspecific interstitial pneumonia (NSIP) pathological pattern, we hypothesized that the prognosis of ARS-ILD might be distinct from that of idiopathic pulmonary fibrosis (IPF) without anti-ARS. OBJECTIVES: To elucidate the long-term outcome of ARS-ILD with and without PM/DM and compare it to that of IPF. METHODS: A two-center retrospective study was conducted. The study population comprised 36 patients with ARS-ILD (8 with PM, 12 with DM, and 16 without myositis throughout the course), 100 patients with IPF without anti-ARS, and 7 patients with NSIP without anti-ARS. The presence of anti-ARS was determined by RNA immunoprecipitation using the sera obtained at the time of diagnosis before specific treatment. MEASUREMENTS AND MAIN RESULTS: During the observational period (median 49 months; range, 1-114 months), 7 patients with ARS-ILD (19%; 3 with PM, 1 with DM, and 3 without PM/DM) and 51 patients with IPF (51%) died. Patients with ARS-ILD had better overall survival than those with IPF (log-rank test, P < 0.001) and similar survival compared to those with NSIP (log-rank test, P = 0.59). The prognosis for patients with ARS-ILD was similar between those with and without myositis (log-rank test, P = 0.91). At the median follow-up time of 76.5 months, 14 of the 36 patients with ARS-ILD had deteriorated. Both a decline in forced vital capacity or an initiation of long-term oxygen therapy during the course (odds ratio [OR], 5.34) and acute exacerbation (OR, 28.4) significantly increased the mortality risk. CONCLUSIONS: The long-term outcome of ARS-ILD was significantly better than that of IPF regardless of the presence or absence of myositis.
[Mh] Termos MeSH primário: Aminoacil-tRNA Sintetases/imunologia
Autoanticorpos/sangue
Dermatomiosite/complicações
Fibrose Pulmonar Idiopática/imunologia
Doenças Pulmonares Intersticiais/imunologia
Miosite/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Autoanticorpos/imunologia
Doenças do Tecido Conjuntivo/complicações
Doenças do Tecido Conjuntivo/diagnóstico
Doenças do Tecido Conjuntivo/imunologia
Doenças do Tecido Conjuntivo/mortalidade
Dermatomiosite/imunologia
Dermatomiosite/mortalidade
Feminino
Seres Humanos
Oxigenação Hiperbárica/métodos
Fibrose Pulmonar Idiopática/complicações
Fibrose Pulmonar Idiopática/diagnóstico por imagem
Doenças Pulmonares Intersticiais/diagnóstico por imagem
Doenças Pulmonares Intersticiais/mortalidade
Masculino
Meia-Idade
Mortalidade
Miosite/mortalidade
Estudos Observacionais como Assunto
Avaliação de Resultados (Cuidados de Saúde)
Prognóstico
RNA/imunologia
Estudos Retrospectivos
Análise de Sobrevida
Capacidade Vital/fisiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 63231-63-0 (RNA); EC 6.1.1.- (Amino Acyl-tRNA Synthetases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  7 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459330
[Au] Autor:Kaner RJ; Brown KK; Martinez FJ
[Ad] Endereço:1 Joan and Sanford I. Weill Department of Medicine Weill Cornell Medicine New York, New York.
[Ti] Título:AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.
[So] Source:Am J Respir Crit Care Med;195(9):1104-1107, 2017 May 01.
[Is] ISSN:1535-4970
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Pulmonares Intersticiais
Publicações Periódicas como Assunto/história
Pneumologia/história
[Mh] Termos MeSH secundário: Aniversários e Eventos Especiais
História do Século XX
História do Século XXI
Seres Humanos
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1164/rccm.201703-0584ED


  8 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320550
[Au] Autor:Bell RD; Rudmann C; Wood RW; Schwarz EM; Rahimi H
[Ad] Endereço:Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
[Ti] Título:Longitudinal micro-CT as an outcome measure of interstitial lung disease in TNF-transgenic mice.
[So] Source:PLoS One;13(1):e0190678, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a debilitating condition with poor survival prognosis. High resolution computed tomography (CT) is a common clinical tool to diagnose RA-ILD, and is increasingly being adopted in pre-clinical studies. However, murine models recapitulating RA-ILD are lacking, and CT outcomes for inflammatory lung disease have yet to be formally validated. To address this, we validate µCT outcomes for ILD in the tumor necrosis factor transgenic (TNF-Tg) mouse model of RA. METHODS: Cross sectional µCT was performed on cohorts of male TNF-Tg mice and their WT littermates at 3, 4, 5.5 and 12 months of age (n = 4-6). Lung µCT outcomes measures were determined by segmentation of the µCT datasets to generate Aerated and Tissue volumes. After each scan, lungs were obtained for histopathology and 3 sections stained with hematoxylin and eosin. Automated histomorphometry was performed to quantify the tissue area (nuclei, cytoplasm, and extracellular matrix) and aerated area (white space) within the tissue sections. Spearman's correlation coefficients were used to evaluate the extent of association between µCT imaging and histopathology endpoints. RESULTS: TNF-Tg mice had significantly greater tissue volume, total lung volume and mean intensity at all timepoints compared to age matched WT littermates. Histomorphometry also demonstrated a significant increase in tissue area at 3, 4, and 5.5 months of age in TNF-Tg mice. Lung tissue volume was correlated with lung tissue area (ρ = 0.81, p<0.0001), and normalize lung aerated volume was correlated with normalized lung air area (ρ = 0.73, p<0.0001). CONCLUSIONS: We have validated in vivo µCT as a quantitative biomarker of ILD in mice. Further, development of longitudinal measures is critical for dissecting pathologic progression of ILD, and µCT is a useful non-invasive method to study lung inflammation in the TNF-Tg mouse model.
[Mh] Termos MeSH primário: Modelos Animais de Doenças
Doenças Pulmonares Intersticiais/diagnóstico por imagem
[Mh] Termos MeSH secundário: Animais
Artrite Reumatoide/complicações
Estudos Longitudinais
Doenças Pulmonares Intersticiais/complicações
Masculino
Camundongos
Camundongos Transgênicos
Microtomografia por Raio-X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190678


  9 / 7278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241348
[Au] Autor:Kim M; Sadoughi B
[Ad] Endereço:1 Sean Parker Institute for the Voice, Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York, USA.
[Ti] Título:The Voice of Autoimmunity: Antisynthetase Syndrome Manifesting as Vocal Fold Bamboo Nodes.
[So] Source:Ann Otol Rhinol Laryngol;127(2):128-130, 2018 Feb.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To describe a case of vocal fold bamboo nodes leading to the diagnosis of antisynthetase syndrome, a rare autoimmune disorder. To highlight the link between these laryngeal lesions and autoimmunity. METHODS: A case of vocal fold bamboo nodes in a patient with long-standing interstitial lung disease is presented. The presence of these characteristic lesions prompted a rheumatologic workup that led to the diagnosis of a rare autoimmune disorder. RESULTS: The patient was ultimately diagnosed with antisynthetase syndrome, a rare condition characterized by inflammatory myositis and interstitial lung disease. She was treated with steroids and immunosuppressive agents with improvement in her symptoms and clinical findings. CONCLUSIONS: Vocal fold bamboo nodes are pathognomonic signs of autoimmunity. Management consists primarily of medical treatment of the underlying systemic disorder. Intralesional steroid injection or phonomicrosurgical excision may be considered for refractory cases.
[Mh] Termos MeSH primário: Doenças Autoimunes/diagnóstico
Disfonia/diagnóstico
Doenças da Laringe/diagnóstico
Doenças Pulmonares Intersticiais/diagnóstico
Doença Mista do Tecido Conjuntivo/diagnóstico
Miosite/diagnóstico
Nódulo Reumatoide/diagnóstico
Prega Vocal/patologia
[Mh] Termos MeSH secundário: Doenças Autoimunes/tratamento farmacológico
Diagnóstico Diferencial
Disfonia/tratamento farmacológico
Disfonia/patologia
Feminino
Seres Humanos
Doenças da Laringe/tratamento farmacológico
Doenças da Laringe/patologia
Laringoscopia
Doenças Pulmonares Intersticiais/tratamento farmacológico
Doenças Pulmonares Intersticiais/patologia
Meia-Idade
Doença Mista do Tecido Conjuntivo/tratamento farmacológico
Miosite/tratamento farmacológico
Prednisona/uso terapêutico
Nódulo Reumatoide/tratamento farmacológico
Nódulo Reumatoide/patologia
Gravação em Vídeo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
VB0R961HZT (Prednisone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE
[do] DOI:10.1177/0003489417748331


  10 / 7278 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245357
[Au] Autor:Chen CF; Chu KA; Tseng YC; Wu CC; Lai RS
[Ad] Endereço:aDivision of Chest Medicine, Department of Internal MedicinebDivision of Thoracic Surgery, Department of SurgerycInstitute of Clinical Medicine, National Yang-Ming University, TaipeidDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, TaiwaneFaculty of Medicine, National Yang-Ming University, Taipei, Taiwan.
[Ti] Título:IgG4-related lung disease presenting as interstitial lung disease with bronchiolitis: A case report.
[So] Source:Medicine (Baltimore);96(49):e9140, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: IgG4-related disease is a rare and novel disease entity that tends to involve multiple organs. The pulmonary manifestation of this disease is highly variable and may mimic lung cancer, pneumonia, interstitial lung disease (ILD), sarcoidosis, and so forth. Small airway disease is rarely reported in IgG4-related lung disease (IgG4-RLD). In the current study, we describe a rare case of IgG4-RLD with patterns of ILD and bronchiolitis. PATIENT CONCERN: A 43-year-old man had chronic cough and dyspnea on exertion for 4 years. Initial chest radiography showed diffuse interstitial infiltration. Follow-up chest computed tomography 4 years later revealed bilateral diffuse centrilobular nodules with tree-in-bud pattern, bronchial wall thickening, and mediastinal lymph nodes. Bilateral diffuse multifocal ground-glass opacities and mosaic attenuation were also observed. Pulmonary function test revealed mixed restrictive and obstructive ventilatory impairment. DIAGNOSES: Video-assisted thoracoscopic surgery (VATS) lung biopsy showed interstitial fibrosis with lymphoplasmacytic infiltration rich in IgG4-positive plasma cells. Serum IgG4 level also showed remarkable elevation. Therefore, IgG4-RLD is confirmed. INTERVENTION: VATS wedge resection of right upper lobe and mediastinal lymph node. OUTCOMES: The patient responded well to steroid and immunosuppression therapy, and was regular followed-up in outpatient clinic. LESSONS: IgG4-RLD should be considered not only in ILD, but also in small airway disease. Serum IgG4 level may be a useful tool for screening.
[Mh] Termos MeSH primário: Imunoglobulina G/imunologia
Pneumopatias/diagnóstico
Pneumopatias/imunologia
[Mh] Termos MeSH secundário: Adulto
Bronquiolite/complicações
Bronquiolite/diagnóstico
Diagnóstico Diferencial
Seres Humanos
Imunossupressores/uso terapêutico
Pneumopatias/tratamento farmacológico
Pneumopatias/patologia
Doenças Pulmonares Intersticiais/complicações
Doenças Pulmonares Intersticiais/diagnóstico
Masculino
Testes de Função Respiratória
Cirurgia Torácica Vídeoassistida
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009140



página 1 de 728 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde